These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 25540902)

  • 1. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
    Balu DT; Coyle JT
    Curr Opin Pharmacol; 2015 Feb; 20():109-15. PubMed ID: 25540902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia.
    Burnet PW; Hutchinson L; von Hesling M; Gilbert EJ; Brandon NJ; Rutter AR; Hutson PH; Harrison PJ
    Schizophr Res; 2008 Jul; 102(1-3):283-94. PubMed ID: 18400471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
    Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.
    Balu DT
    Adv Pharmacol; 2016; 76():351-82. PubMed ID: 27288082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
    Labrie V; Roder JC
    Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
    Karasawa J; Hashimoto K; Chaki S
    Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.
    Coyle JT; Tsai G
    Psychopharmacology (Berl); 2004 Jun; 174(1):32-8. PubMed ID: 15205876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of negative and cognitive symptoms.
    Javitt DC
    Curr Psychiatry Rep; 1999 Oct; 1(1):25-30. PubMed ID: 11122902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
    Fone KCF; Watson DJG; Billiras RI; Sicard DI; Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Mol Neurobiol; 2020 May; 57(5):2144-2166. PubMed ID: 31960362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.